Versuchen GOLD - Frei

Can Cutting-edge Tech Reduce Rising CVD Burden?

BioSpectrum Asia

|

BioSpectrum Asia Dec 2023

Each year World Heart Day is observed to increase awareness about cardiovascular diseases (CVDs), after all defeating them is something that matters to every beating heart. CVDs are disorders of the heart and blood vessels and are often referred to as “silent killers” because most of the patients with underlying heart ailments do not exhibit any obvious symptoms. Development and deployment of cutting-edge technologies backed by requisite government policy support and direction will help in bolstering the fight against CVDs and thus improving the quality of the individuals’ heart and also their lives. Let’s take a closer look.

Can Cutting-edge Tech Reduce Rising CVD Burden?

India is rapidly becoming the global CVDs epicentre which is primarily attributed to a mix of genetics, poor cultural practices and lifestyle factors among Indians such as increased trans fatty acids content in foods due to repeated use of cooking oil, unique pattern of atherogenic dyslipidaemia, consumption of processed and read-to eat foods, physical inactivity, obesity, high tobacco use, and increased stress levels that have contributed towards the increased prevalence of CVDs.

According to the Lancet’s Global Burden of Disease study, India has an age-standardised CVD death rate of 282 per 100,000 population which is remarkably higher than the global average of 233 deaths per 100,000. The key to managing CVDs is early detection which can help identify the risk of cardiovascular diseases before it becomes too late. The industry is making tremendous efforts to reduce the disease burden, technology advancements in digital health and MedTech have enabled disease detection at an early stage, and also helped disease management of high-risk patients.

Technologies such as artificial intelligence (AI)based medical imaging analysis and precise screening solutions, continuous monitoring wearables and digital therapeutics have emerged as key enablers for the prevention and management of CVD in India. These technologies can play a vital role in lowering CVD risk and reducing the associated mortality rate which is especially important for a country that accounts for 60 per cent of the world’s disease burden. Some of these technologies to reduce cardiac disease burden are given below.

AI-based medical imaging analysis and screening solutions

WEITERE GESCHICHTEN VON BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

India signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

New Zealand to lead new gene therapy trial for muscular dystrophy

The first clinical trial of a new treatment for a rare form of muscular dystrophy is being led by New Zealand-based University of Auckland's Centre for Brain Research.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Scientists in Australia grow living skin in world-first

Australia's University of Queensland (UQ) researchers have been the first in the world to successfully grow fully functioning human skin in a laboratory.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

India joins Health AI Global Regulatory Network to strengthen oversight of AI in healthcare

HealthAI - The Global Agency for Responsible AI in Health, has welcomed India as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of artificial intelligence (AI) in healthcare.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

TVM Capital Healthcare announces first closing of $150 M Southeast Asia Fund

Singapore-based TVM Capital Healthcare, a global private equity investor and operator specialised in healthcare growth capital across emerging markets, has announced the first closing of its $150 million TVM Healthcare Southeast Asia Fund (SEA Fund).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

National Yang Ming Chiao Tung University, TSH Biopharm collaborate to foster pharma talent in Taiwan

Taiwan's National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm have signed a five-year industry-academia collaboration Memorandum of Understanding (MOU).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Fujifilm Biosciences introduces BalanCD HEK293 Perfusion A Medium

Fujifilm Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, has announced the commercial launch of BalanCD HEK293 Perfusion A.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Korea makes smart patch that can run tests using sweat instead of blood

A research team at Korea Advanced Institute of Science and Technology has developed a smart patch that can precisely observe internal changes through sweat when simply attached to the body.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

ADB approves $106.9 M to strengthen secondary healthcare services in Sri Lanka

The Asian Development Bank (ADB) has approved a $106.9 million financing package to strengthen Sri Lanka's secondary curative care services, improve communicable disease prevention and control, and enhance the healthcare sector's governance and management capacity.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Epigenic Therapeutics raises $60 M to accelerate clinical development of medicines

China-based startup Epigenic Therapeutics, a clinical-stage innovative drug development company, has announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry.

time to read

1 min

BioSpectrum Asia Oct 2025

Translate

Share

-
+

Change font size